Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Myeloid Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT06478693
- Locations
- 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Integrated Clinical Oncology Network (ICON) Pty Ltd, Woolloongabba, Queensland, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
- Conditions
- Epithelial Tumors, Malignant
- Interventions
- Drug: MT-302 (A)
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Myeloid Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT05969041
- Locations
- 🇦🇺
St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
- Conditions
- Lymphoma, T-Cell, PeripheralMycosis FungoidesCell TherapyLymphoma, T-Cell, CutaneousAdoptive Cellular Immunotherapy
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Myeloid Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05138458
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Dana-Farber/Mass General Brigham Cancer Care, Boston, Massachusetts, United States
News
Myeloid Therapeutics Reports First-in-Human Data for In Vivo mRNA CAR Therapies at ASCO 2025
Myeloid Therapeutics presented first-in-human data for MT-302 and MT-303, marking the first clinical applications of systemically administered in vivo mRNA CAR therapies.
Myeloid Therapeutics' MT-303, a Novel mRNA CAR Therapy, Enters Phase 1 Trial for Liver Cancer
MT-303, a GPC3-targeting CAR mRNA therapy, is being evaluated in a Phase 1 trial (NCT06478693) for advanced hepatocellular carcinoma (HCC).
In Vivo CAR T-Cell Therapies Advance to Clinical Trials, Promising Faster, Cheaper Cancer Treatment
In vivo CAR T-cell generation uses off-the-shelf reprogramming cassettes, potentially reducing manufacturing time and costs compared to ex vivo CAR Ts.